Anagliptin

Anagliptin

Anagliptin is an oral antidiabetic drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which work by increasing the levels of incretin hormones, thereby enhancing the secretion of insulin and decreasing the production of glucagon in a glucose-dependent manner.

Mechanism of Action

Anagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing the breakdown of these hormones, anagliptin increases their levels in the bloodstream, leading to improved glycemic control. The increased incretin levels result in enhanced insulin secretion from the pancreatic beta cells and reduced glucagon release from the pancreatic alpha cells, which helps to lower blood glucose levels.

Indications

Anagliptin is indicated for the treatment of type 2 diabetes mellitus in adults. It is typically used in combination with other antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones when diet and exercise alone do not provide adequate glycemic control.

Dosage and Administration

The recommended dose of anagliptin is usually 100 mg taken orally twice daily. The dosage may be adjusted based on the patient's response and tolerability. It is important to follow the prescribing physician's instructions and not to exceed the recommended dose.

Side Effects

Common side effects of anagliptin include:

• Nasopharyngitis
• Headache
• Upper respiratory tract infection
• Hypoglycemia (when used in combination with other antidiabetic drugs)

Serious but rare side effects may include:

• Pancreatitis
• Hypersensitivity reactions

Contraindications

Anagliptin is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It should be used with caution in patients with a history of pancreatitis.

Related Pages

• Type 2 diabetes mellitus
• Dipeptidyl peptidase-4 inhibitors
• Incretin
• Insulin
• Glucagon
• Metformin
• Sulfonylureas
• Thiazolidinediones

External Links

-